Introduction. Melanoma aggressive and fatal form of skin cancer that originates in the pigment-producing cells (melanocyte), have a high mortality rate due to the resistance of most tumors to chemotherapy. This is a reason to explore alternate therapies for this disease. One of cancer treatments that has seen intensive development recently is oncolytic immunotherapy. The essence of this approach is that use of viruses as tumor-specific cytolytic agents capable of stimulating both the tumor-specific and non-specific immune response. There is considerable research devoted to improving the immunostimulating properties of viruses by insert into the viral genome the genes encoding immunomodulatory proteins or the artificial tumor-specific polyepitopic immunogens. The highest number of tumor-associated antigens was identified for melanoma, on the basis of which anti-tumor DNA vaccines are developed. Immunogenicity and efficacy of such drugs remain low. The problem with the use of DNA vaccines for treating cancer may be the incorrect design of the polyepitopic construct, as well as the inefficient delivery of therapeutic molecules directly to the target cells. A partial solution to this problem may be use of oncolytic viruses as a vector to deliver artificial immunogens. Materials and methods. MTT test, methods of transient dominant selection, murine xenograft model using malignant cells SK-Mel-28. Results and discussion. In this study, a recombinant L-IVP_oncoM virus was obtained on the basis of the vaccinia virus strain L-IVP, which is an oncolytic virus that delivers anticancer therapeutic genes to the cells of the body. For this purpose, a gene encoding GM-CSF and an artificial gene encoding a polyepitopic immunogen consisting of epitopes of antigens over-expressed in melanoma cells were inserted into the genome of the virus. These insertions were performed in the region of the genes encoding thymidine kinase (J2R) and viral growth factor (C11L), respectively. The properties of L-IVP_oncoM were studied in a series of in vitro/in vivo experiments. Conclusion. The basic experiments on the evaluation of the biological properties of the obtained L-IVP_oncoM, which are necessary for the characterization of the oncolytic virus, have been carried out.